Search Results
May 13, 2026, 01:17 ET dcamp、東京「TAKANAWA GATEWAY CITY」でオープンイノベーションを本格化
dcampはJR東日本と協力し、5月12日、日本・東京の「TAKANAWA GATEWAY CITY」内にあるビジネス創造施設「TAKANAWA GATEWAY Link Scholars' Hub（LiSH）」で、「スタートアップ OI 東京 #スマートシティ」プログラムを運営し、韓国スタートアップ企業の技術を現地の都市環境に適用する実証（PoC）機会を設けた。実証の舞台となるのは、JR東日本が推進する駅と街が一体となった国内最大規模の街「TAKANAWA GTAEWAY CITY」。街全体を「100年先の心豊かな
More news about: dcamp
Apr 30, 2026, 06:50 ET Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
Operating Income ("OI")$ 380.8
More news about: Labcorp Holdings Inc
Apr 24, 2026, 07:37 ET 嘉里建設呈獻亞洲冰球盛事 「2026 Mega Ice五人冰球賽」4月23日開鑼 逾百支球隊雲集香港競技 推廣冰球運動文化
香港明愛 Caritas Hong Kong Yan Oi Tong 基督教家庭服務中心
More news about: Mega Ice
Apr 22, 2026, 16:01 ET TI reports first quarter 2026 financial results and shareholder returns
1,324Other income (expense), net (OI&E)
More news about: Texas Instruments Incorporated
Apr 06, 2026, 03:44 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Apr 05, 2026, 16:59 ET MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Apr 04, 2026, 16:00 ET RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Apr 04, 2026, 07:47 ET RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Apr 02, 2026, 19:29 ET The Asian American Foundation Donates $350,000 to San Francisco Nonprofits as Part of 'Asian American Voices' Initiative
Communities As One, to invest in programming and infrastructure upgrades at the Yik Oi Huang Peace and Friendship Park.
More news about: The Asian American Foundation
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 31, 2026, 18:37 ET MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 30, 2026, 17:28 ET RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 30, 2026, 02:35 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Mar 29, 2026, 08:14 ET RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 25, 2026, 22:52 ET MREO Deadline: MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 25, 2026, 18:48 ET RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 22, 2026, 08:33 ET RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Mar 20, 2026, 14:24 ET MREO Deadline: MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 19, 2026, 20:50 ET Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
Adipocyte-Apoptosis Agent Enhances GLP-1 Induced Weight Loss and Attenuates Weight Regain In Diet-Induced Obese Rats."After Caliway first shared OI23 data with industry experts during the European Association for the Study of Diabetes (EASD) last year, the findings attracted strong interest from
More news about: Caliway Biopharmaceuticals
Mar 19, 2026, 20:09 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP